Metabolic dependencies and targets in ovarian cancer
- PMID: 37059310
- DOI: 10.1016/j.pharmthera.2023.108413
Metabolic dependencies and targets in ovarian cancer
Abstract
Reprogramming of cellular metabolism is a hallmark of cancer. Cancer cells undergo metabolic adaptations to maintain tumorigenicity and survive under the attack of immune cells and chemotherapy in the tumor microenvironment. Metabolic alterations in ovarian cancer in part overlap with findings from other solid tumors and in part reflect unique traits. Altered metabolic pathways not only facilitate ovarian cancer cells' survival and proliferation but also endow them to metastasize, acquire resistance to chemotherapy, maintain cancer stem cell phenotype and escape the effects of anti-tumor immune defense. In this review, we comprehensively review the metabolic signatures of ovarian cancer and their impact on cancer initiation, progression, and resistance to treatment. We highlight novel therapeutic strategies targeting metabolic pathways under development.
Keywords: Endoplasmic reticulum stress; Glutamine; Glycolysis; Lipids; Metabolism; Ovarian cancer; Oxidative phosphorylation; Reactive oxygen species.
Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest YZ is now employed by Bain & Company. GZ is now employed by Tempus. DM reports consulting fees from Astra Zeneca, Glaxo SmithKline, GOG Foundation, Elsevier, Eisai and research funding from Merck, Pinot Bio, and Abbvie, unrelated to this manuscript.
Similar articles
-
Alteration of glucose metabolism and expression of glucose transporters in ovarian cancer.Explor Target Antitumor Ther. 2024;5(2):384-399. doi: 10.37349/etat.2024.00224. Epub 2024 Apr 24. Explor Target Antitumor Ther. 2024. PMID: 38745772 Free PMC article. Review.
-
Organoid models of ovarian cancer: resolving immune mechanisms of metabolic reprogramming and drug resistance.Front Immunol. 2025 Mar 21;16:1573686. doi: 10.3389/fimmu.2025.1573686. eCollection 2025. Front Immunol. 2025. PMID: 40191206 Free PMC article. Review.
-
Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells.Sci Rep. 2017 Aug 18;7(1):8760. doi: 10.1038/s41598-017-09206-0. Sci Rep. 2017. PMID: 28821788 Free PMC article.
-
Perspectives of Reprogramming Breast Cancer Metabolism.Adv Exp Med Biol. 2017;1026:217-232. doi: 10.1007/978-981-10-6020-5_10. Adv Exp Med Biol. 2017. PMID: 29282686 Review.
-
Altered metabolism in cancer: insights into energy pathways and therapeutic targets.Mol Cancer. 2024 Sep 18;23(1):203. doi: 10.1186/s12943-024-02119-3. Mol Cancer. 2024. PMID: 39294640 Free PMC article. Review.
Cited by
-
Ginsenoside 20(S)-Rg3 upregulates SQLE to reprogram cholesterol metabolism of ovarian cancer cells.iScience. 2025 Jul 1;28(8):112853. doi: 10.1016/j.isci.2025.112853. eCollection 2025 Aug 15. iScience. 2025. PMID: 40792023 Free PMC article.
-
A lactate metabolism-related signature predicting patient prognosis and immune microenvironment in ovarian cancer.Front Endocrinol (Lausanne). 2024 Mar 11;15:1372413. doi: 10.3389/fendo.2024.1372413. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38529390 Free PMC article.
-
Glutamine metabolism prognostic index predicts tumour microenvironment characteristics and therapeutic efficacy in ovarian cancer.J Cell Mol Med. 2024 Apr;28(7):e18198. doi: 10.1111/jcmm.18198. J Cell Mol Med. 2024. PMID: 38506093 Free PMC article.
-
Phosphorylation of FOXK2 at Thr13 and Ser30 by PDK2 sustains glycolysis through a positive feedback manner in ovarian cancer.Oncogene. 2024 Jun;43(26):1985-1999. doi: 10.1038/s41388-024-03052-x. Epub 2024 May 11. Oncogene. 2024. PMID: 38734828 Free PMC article.
-
Competing endogenous RNA networks in ovarian cancer: from bench to bedside.EXCLI J. 2025 Jan 7;24:86-112. doi: 10.17179/excli2024-7827. eCollection 2025. EXCLI J. 2025. PMID: 39967908 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical